Adaptive Biotechnologies Corporation — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Adaptive is a commercial-stage biotechnology company focused on immune-receptor sequencing and related diagnostics, research services, and therapeutic discovery. Its principal business areas are minimal residual disease (MRD), including clonoSEQ, and Immune Medicine (IM), including immunoSEQ, pharma services, and drug discovery.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $185.3 million | $154.3 million | +20% |
| Cost of revenue | $57.9 million | $49.3 million | +17% |
| Gross margin | 68.8% | 68.1% | +0.7 percentage points |
| Total operating expenses | $385.5 million | $363.3 million | +6% |
| Operating loss | $(200.2) million | $(209.0) million | Loss narrowed |
| Net loss attributable to Adaptive | $(200.2) million | $(207.3) million | Loss narrowed |
| Adjusted EBITDA (non-GAAP) | $(121.6) million | $(151.7) million | Improved by $30.2 million |
| Cash used in operating activities | $(183.9) million | $(192.7) million | Use decreased |
- Revenue mix: IM revenue was $98.2 million, up 11%; MRD revenue was $87.1 million, up 32%. clonoSEQ test volume rose 51% to 36,871.
- Cash, cash equivalents, and marketable securities totaled $498.2 million at year-end, down from $570.2 million. Current assets were $562.1 million and current liabilities were $109.8 million.
- In September 2022, the company received $124.4 million net under an OrbiMed revenue-interest agreement. The reported revenue-interest liability was $125.4 million at year-end; the agreement provides for payments based on 5% of quarterly revenue with only the initial payment funded, and grants security interests in core platform assets.
- Undiscounted operating lease commitments were $135.3 million. The filing reports no material legal proceedings at year-end.
Material changes and operating developments
- MRD service revenue increased with greater clonoSEQ clinical use and biopharma testing; MRD regulatory milestone revenue fell to $6.0 million from $10.0 million.
- IM pharma services revenue increased 67%. The Genentech collaboration generated $62.8 million of 2022 revenue; clonoSEQ and Genentech together remained important revenue sources.
- The company reorganized around MRD and IM and reduced its workforce by approximately 100 employees, incurring $2.0 million in restructuring costs, paid by year-end.
- Adaptive deferred further commercialization of T-Detect COVID and T-Detect Lyme, citing commercialization costs and the need for stronger evidence and a clearer reimbursement path.
- For Genentech’s shared-product program, Genentech selected a TCR candidate to advance as a potential cell therapy. Adaptive also reported proof of concept for identifying patient-specific TCRs; these programs remain developmental.
Outlook, commentary, and key risks
- Management said it expects positive adjusted EBITDA by the end of 2025, cash-flow breakeven by the end of 2026, and 20%–30% revenue compound annual growth through 2027, with operating expenses growing more slowly. These are forward-looking targets, not guarantees.
- Management stated that existing cash and marketable securities should fund anticipated requirements for at least 12 months from the filing’s assessment. The company continued to use substantial cash in operations and may seek additional financing.
- Revenue concentration merits attention: the filing says Genentech accounted for 33.9% of revenue in 2022, while its customer-concentration table reports Genentech/Roche at 36.4%. The figures may reflect different definitions and should be reconciled.
- Genentech controls clinical, regulatory, and commercialization decisions under the collaboration, may terminate for convenience, and potential milestone and royalty receipts depend on future development and commercial success. The filing identifies revenue recognition for this agreement as a critical audit matter because estimates depend on expected development costs and timelines.
- Other material risks include continued losses, reimbursement and clinical-adoption uncertainty, regulation of laboratory-developed tests, competition, reliance on Illumina as a key sequencing supplier, and execution risks in early-stage therapeutic discovery. The revenue-interest financing also reduces future revenue available for operations and is secured by core platform assets.
Most important facts for investors to verify
- Whether clonoSEQ volume growth and new coverage, especially for DLBCL, translate into durable revenue, reimbursement, and improved unit economics.
- Revenue concentration and the difference between the disclosed Genentech revenue share and the Genentech/Roche customer concentration figure.
- Progress toward the stated 2025 adjusted EBITDA and 2026 cash-flow breakeven targets, including cash burn, operating expense growth, and financing needs.
- The revenue-interest agreement’s actual quarterly payments, effective cost, collateral and covenant implications, and availability of the potential additional installments.
- Whether Genentech programs advance to clinical development and achieve milestones, and whether IM pharma services growth persists as customer studies evolve.
- Future clinical evidence, reimbursement, and regulatory developments for clonoSEQ and any renewed T-Detect commercialization plans.
The independent auditor issued unqualified opinions on the consolidated financial statements and on internal control over financial reporting as of December 31, 2022.